RAI1 alternate probe identifies additional gastroesophageal adenocarcinoma cases as amplified following equivocal HER2 fluorescence in situ hybridization testing: experience from a national reference laboratory-Reference-Cited by-同舟云学术

RAI1 alternate probe identifies additional gastroesophageal adenocarcinoma cases as amplified following equivocal HER2 fluorescence in situ hybridization testing: experience from a national reference laboratory

Published:2021-10-18 Issue: Volume: Page:
ISSN:0893-3952
Container-title:Modern Pathology
language:en
Short-container-title:Mod Pathol

Author:

Jedrzkiewicz Jolanta,Sirohi Deepika,Uvejzovic Nermin,Gulbahce H. Evin

Publisher

Springer Science and Business Media LLC

Subject

Pathology and Forensic Medicine

Link

https://www.nature.com/articles/s41379-021-00933-4.pdf

Reference19 articles.

1. Haffner, I. et al. HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: results From the Prospective Multicenter VARIANZ Study. J. Clin. Oncol. 39, 1468–1478 (2021).

2. Janjigian, Y. Y. et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann. Oncol. 23, 2656–2662 (2012).

3. Hudis, C. A. Trastuzumab-mechanism of action and use in clinical practice. N. Engl. J. Med. 357, 39–51 (2007).

4. Bang, Y. J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376, 687–697 (2010).

5. Bartley, A. N. et al. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology. Am. J. Clin. Pathol. 146, 647–669 (2016).

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fluorescent probe applications and prospects in gastrointestinal cancer: A bibliometric analysis;European Journal of Surgical Oncology;2024-10